Medical regulation of treatments for children and young people remains a central responsibility of UK health authorities, particularly where long-term outcomes are uncertain. Clinical trials involving minors are subject to enhanced scrutiny to ensure participant welfare and scientific justification.
The Department of Health and Social Care confirmed that preliminary work on the PATHWAYS clinical trial has been paused following new concerns raised by the Medicines and Healthcare products Regulatory Agency about the prescription of puberty blockers for young people with gender incongruence.
The Department of Health and Social Care said recruitment will not begin until these issues are addressed through discussions with the trial sponsor, King’s College London, with the study proceeding only if evidence confirms it is safe and necessary.
MHRA Raises New Safety Concerns
The Medicines and Healthcare products Regulatory Agency reported new concerns directly related to the wellbeing of children and young people who would participate in the trial. As the UK’s medicines regulator, the MHRA oversees the safety and scientific validity of clinical research involving medicinal products.
- Participant safety considerations
- Scientific evidence requirements
Trial Preparations Halted Pending Review
Officials confirmed that preparatory activities for the study have been paused while the regulator’s concerns are examined. Recruitment of participants will not begin until the MHRA and clinical leaders agree that the issues have been addressed.
- Recruitment postponed
- Preparatory work suspended
Scientific Dialogue With Trial Sponsor
Formal discussions are due to take place between the MHRA and King’s College London to review the evidence supporting the trial. The dialogue will focus on whether the study design and safeguards meet regulatory expectations.
Safety Oversight Framework
| Regulator | MHRA assesses safety, evidence, and compliance requirements |
| Trial Sponsor | King’s College London responsible for study conduct and data |
| Clinical Teams | Provide medical oversight for participants |
Government Position on Children’s Wellbeing
The Department of Health and Social Care reiterated that the safety and wellbeing of young people is the central consideration in decisions about the trial. Officials stated that the study will proceed only if expert scientific advice confirms it is both safe and necessary.
Decision Conditions for Trial Approval
| Safety Assurance | Evidence must demonstrate acceptable risk to participants |
| Clinical Necessity | Experts must conclude the trial is required |
| Regulatory Approval | MHRA concerns must be resolved before recruitment |
Stakeholder Comments
Department of Health and Social Care spokesperson said;
“We have always been clear about the red lines regarding this trial – ensuring the safety and wellbeing of the children and young people involved and always being led by the clinical evidence. The MHRA has now raised new concerns – directly related to the wellbeing of children and young people – and scientific dialogue will now follow with the trial sponsor.”
In a Nutshell
Preparations for the PATHWAYS clinical trial will remain on hold while regulators and clinicians review newly identified safety concerns. The government has indicated that the study will move forward only if evidence supports both safety and necessity.
Discussions between the MHRA and the trial sponsor are expected to determine whether recruitment can begin under revised conditions.
Sources: Department of Health and Social Care, Medicines and Healthcare products Regulatory Agency (MHRA).
Prepared by Ivan Alexander Golden, Founder of THX News, an independent news organisation delivering timely insights from global official sources. Combines AI-analysed research with human-edited accuracy and context.
